Provided by Tiger Trade Technology Pte. Ltd.

MediciNova

1.56
+0.01000.65%
Post-market: 1.51-0.0500-3.21%19:41 EST
Volume:99.60K
Turnover:156.51K
Market Cap:76.51M
PE:-6.37
High:1.60
Open:1.56
Low:1.55
Close:1.55
52wk High:2.37
52wk Low:1.13
Shares:49.05M
Float Shares:42.08M
Volume Ratio:1.41
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2449
EPS(LYR):-0.2253
ROE:-24.26%
ROA:-15.82%
PB:1.74
PE(LYR):-6.92

Loading ...

MediciNova Inc - May Offer up to $300 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Yesterday

MediciNova Reveals MN-001 Metabolite Boosts Cholesterol Efflux in Macrophages

Reuters
·
Dec 02

Message from the CEO to MediciNova Shareholders

GlobeNewswire
·
Dec 02

MediciNova names Dr. Christopher Breder as Clinical and Regulatory Advisor

TIPRANKS
·
Nov 18

Press Release: MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

Dow Jones
·
Nov 18

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

GlobeNewswire
·
Nov 07

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 04

BRIEF-MediciNova Completes Patient Enrollment In MN-001 Trial For Tipelukast In MN-001-NATG-202 Study

Reuters
·
Nov 04

MediciNova Completes Enrollment in Phase 2 Trial of Tipelukast for NAFLD and Hypertriglyceridemia

Reuters
·
Nov 04

Medicinova Announces Completion of Patient Enrollment in Mn-001-Natg-202 Clinical Trial of Mn-001 (Tipelukast)

THOMSON REUTERS
·
Nov 04

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

GlobeNewswire
·
Nov 04

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 31

Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?

Benzinga_recent_news
·
Oct 31

MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis

TIPRANKS
·
Oct 31

MediciNova Reports Positive Results for Tipelukast in Cholesterol Metabolism Study

Reuters
·
Oct 31

MediciNova Inc. to Present Corporate Overview at LD Micro Main Event XIX Investor Conference

Reuters
·
Oct 06

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Sep 22

MediciNova Completes Patient Enrollment for Phase 2b/3 ALS Trial of MN-166

Reuters
·
Sep 22

Medicinova Announces Completion of Patient Enrollment in Combat-ALS Phase 2B/3 Clinical Trial of Mn-166 (Ibudilast)

THOMSON REUTERS
·
Sep 22

Medicinova Announces Poster Presentation of Combat-ALS Clinical Trial at the 36TH International Symposium on ALS/Mnd

THOMSON REUTERS
·
Sep 16